May 15, 2015
Mylan Pharmaceuticals Inc. told a Pennsylvania federal judge Thursday that it would urge the Third Circuit to overturn his ruling that tossed the generic-drug maker's allegations that Warner Chilcott PLC tried to block generic competition for its acne medication Doryx by tweaking its formula.
April 16, 2015
A Pennsylvania federal judge on Thursday tossed Mylan Pharmaceuticals Inc.'s allegations that Warner Chilcott PLC tried to block generic competition for its acne medication Doryx by tweaking its formula, ruling any damage Mylan suffered was due to its own business strategy.
July 14, 2014
Warner Chilcott PLC promised Friday to pay $8 million to settle antitrust claims made in Pennsylvania federal court by indirect purchasers of the acne medication Doryx, who said the company prevented a generic version of the drug from coming to market.
May 02, 2014
Warner Chilcott PLC has taken a shot at Mylan Pharmaceuticals Inc.'s bid for summary judgment in its lawsuit alleging Warner had tried to block generic competition to the acne medication Doryx by tweaking the pill, arguing that the company's "product hopping" theory did not hold up.
November 20, 2013
A Pennsylvania federal judge on Wednesday denied a bid to certify a proposed class of indirect purchasers who are accusing Warner Chilcott PLC of making small tweaks to its severe acne medication Doryx as a tactic to stave off generics.
June 12, 2013
A Pennsylvania federal judge Wednesday denied Warner Chilcott PLC's motions to dismiss several complaints in a consolidated antitrust dispute alleging it had tried to block generic competition to the acne medication Doryx by tweaking the pill, saying the motions were premature.
May 29, 2013
An antitrust lawsuit accusing Warner Chilcott PLC of attempting to stymie a generic version of the acne medication Doryx "falls woefully short" of the requirements for class action certification, the company told a Pennsylvania federal court Wednesday.
March 08, 2013
Walgreen Co., Safeway Inc. and other retailers struck back Thursday against Warner Chilcott PLC's attempt to upend their antitrust suit over the drugmaker's efforts to stymie a generic form of Doryx, saying the manufacturer is "confused" about contractual terms it's citing as roadblocks to the litigation.
February 28, 2013
Warner Chilcott PLC said Wednesday that contracts it has with Doryx wholesalers prevent Walgreen Co., Safeway Inc. and two other retailers from suing the drugmaker in Pennsylvania for allegedly preventing competitors from developing a lower-cost generic version of the skin infection treatment.
November 27, 2012
The Federal Trade Commission has told the Pennsylvania federal court considering a consolidated antitrust suit against Warner Chilcott PLC that minor, nontherapeutic changes to a branded drug can represent exclusionary conduct and harm competition from generics makers, the agency said Tuesday.